Neuroinflammatory Proteins in Huntington’s Disease: Insights into Mechanisms, Diagnosis, and Therapeutic Implications
International Journal of Molecular Sciences · 02.11.2024 · 25 (21) · 11787
DOI: 10.3390/ijms252111787 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 02.11.2024. Verfasst von Xinhui Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Key Laboratory of Non-Human Primate Research, Key Laboratory of CNS Regeneration (Ministry of Education), Guangdong-Hongkong-Macau Institut…. Hauptthemen laut MEDLINE: Huntington Disease. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 211 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Key R&D Program of China, the National Science Foundation of China, the Guangzhou Key Research Program on Brain Science.
Abstract (Originalsprache)
Huntington’s disease (HD) is a hereditary neurodegenerative disorder caused by a CAG tract expansion in the huntingtin gene (HTT). HD is characterized by involuntary movements, cognitive decline, and behavioral changes. Pathologically, patients with HD show selective striatal neuronal vulnerability at the early disease stage, although the mutant protein is ubiquitously expressed. Activation of the immune system and glial cell-mediated neuroinflammatory responses are early pathological features and have been found in all neurodegenerative diseases (NDDs), including HD. However, the role of inflammation in HD, as well as its therapeutic significance, has been less extensively studied compared to other NDDs. This review highlights the significantly elevated levels of inflammatory proteins and cellular markers observed in various HD animal models and HD patient tissues, emphasizing the critical roles of microglia, astrocytes, and oligodendrocytes in mediating neuroinflammation in HD. Moreover, it expands on recent discoveries related to the peripheral immune system’s involvement in HD. Although current immunomodulatory treatments and inflammatory biomarkers for adjunctive diagnosis in HD are limited, targeting inflammation in combination with other therapies, along with comprehensive personalized treatment approaches, shows promising therapeutic potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guangdong Key Laboratory of Non-Human Primate Research, Key Laboratory of CNS Regeneration (Ministry of Education), Guangdong-Hongkong-Macau Institute of CNS Regeneration, Jinan University, Guangzhou 510632, China.
- Department of Neurosurgery, The First Affiliated Hospital of Jinan University, Guangzhou 510630, China.
ORCID-Profile: Huichun Tong, Tianqi Yang, Sitong Yang, Shihua Li
Förderung
- the National Key R&D Program of China
- the National Science Foundation of China
- the Guangzhou Key Research Program on Brain Science
- National Key R&D Program of China
- National Science Foundation of China
- Guangzhou Key Research Program on Brain Science
Zitieren
APA
Li, X., Tong, H., Xu, S., Zhou, G., Yang, T., Yin, S., Yang, S., Li, X., & Li, S. (2024). Neuroinflammatory Proteins in Huntington’s Disease: Insights into Mechanisms, Diagnosis, and Therapeutic Implications. International Journal of Molecular Sciences, 25(21), 11787. https://doi.org/10.3390/ijms252111787
Vancouver
Li X, Tong H, Xu S, Zhou G, Yang T, Yin S, et al. Neuroinflammatory Proteins in Huntington’s Disease: Insights into Mechanisms, Diagnosis, and Therapeutic Implications. International Journal of Molecular Sciences. 2024;25(21):11787. doi:10.3390/ijms252111787
BibTeX
@article{Li2024,
author = {Li, Xinhui and Tong, Huichun and Xu, Shuying and Zhou, Gongke and Yang, Tianqi and Yin, Shurui and Yang, Sitong and Li, Xiaojiang and Li, Shihua},
title = {Neuroinflammatory Proteins in Huntington’s Disease: Insights into Mechanisms, Diagnosis, and Therapeutic Implications},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {21},
pages = {11787},
doi = {10.3390/ijms252111787}
}
EUVIMED